Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies

OBJECTIVE:To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain.METHODS:Elaris Endometriosis (EM)-III and -IV were extension studies that evaluated an additional 6 months of treatment